ZILBRYSQ® is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti‑acetylcholine receptor (AChR) antibody positive.
Zilucoplan RMP Educational Materials
These essential resources contain important information to minimize the risk of meningococcal infection associated with Zilucoplan.
The patient or, if appropriate, their caregiver should be educated about treatment risks and provided with a Patient Alert Card. It is important for patients treated with Zilucoplan to always carry the Patient Alert Card with them throughout treatment and for two months after their last dose.
Please refer to the Summary of Product Characteristics for more detailed safety information about Zilucoplan.
If you have any further questions, please contact UCB-Pharma AG:
Phone: +41 (0) 58 822 31 80
E-Mail: BullePharmaMedinfo@ucb.com
IMPORTANT INFORMATION
Vaccination Confirmation
To minimize the risk of potential meningococcal infection with ZILBRYSQ® (Zilucoplan), ZILBRYSQ® can be dispensed only after written confirmation that the patient has received meningococcal vaccination. The supplier will not be able to process any orders for patients for whom a vaccination has not been confirmed.
Instructions on how to confirm that your patient has been vaccinated and to complete the Declaration of Vaccination are available at: https://hcp.zilucoplancap.eu/che.
Download of Zilucoplan RMP Educational Materials
German:
Information on zilucoplan and how to manage risks
Important safety information for patients and their carers
Important safety information that patients should always carry with them
Important information for dispensing pharmacists in relation to the zilucoplan controlled access program
French:
Information on zilucoplan and how to manage risks
Important safety information for patients and their carers
Important safety information that patients should always carry with them
Important information for dispensing pharmacists in relation to the zilucoplan controlled access program
Italian:
Information on zilucoplan and how to manage risks
Important safety information for patients and their carers
Important safety information that patients should always carry with them
Important information for dispensing pharmacists in relation to the zilucoplan controlled access program
Reporting of Adverse Events
Healthcare professionals should report suspected adverse reactions, especially meningococcal infections, via the ElViS portal (Electronic Vigilance System) at the following link: Reporting of adverse drug reactions for healthcare professionals (swissmedic.ch)
Please provide as much information as possible when reporting suspected adverse reactions, including comorbidities, past medical history, concomitant medication, and relevant timings and dates.
Alternatively, suspected side effects can be reported to UCB at:
UCB-Pharma AG
Chem. de la Croix-Blanche 10
1630 Bulle
Switzerland
Phone: +41 (0)58 822 3180
E-Mail: 2ds.ch@ucb.com
qThis medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare Professionals are asked to report any suspected adverse reactions. Healthcare Professionals should report suspected adverse reactions via the ElViS portal (Electronic Vigilance System).
CH-ZL-2400062, Date of preparation: January 2025
You are about to leave www.ucbsuisse.ch.
Dieser Link öffnet in einem neuen Fenster eine Webseite eines anderen Anbieters, für deren Inhalte die UCB Pharma GmbH nicht verantwortlich ist.
You are about to leave www.ucbsuisse.ch.
Dieser Link öffnet in einem neuen Fenster eine Webseite eines anderen Anbieters, für deren Inhalte die UCB Pharma GmbH nicht verantwortlich ist.
Choose Country
- Global Site – English
- Australia – English
- België – Engels
- Belgique – Anglais
- Brasil – Português
- България – Български
- Canada – English
- Canada – Français
- 中国 – 中文
- Česká Republika – Angličtina
- Danmark – Engelsk
- Deutschland – Deutsch
- France – Français
- España – Español
- Ελλάδα – Ελληνικά
- India – English
- Ireland – English
- Italia – Inglese
- 日本 – 日本語
- Казахстан – ағылшын тілі
- 한국 – 한국어
- Luxembourg – Anglais
- Luxemburg – Engels
- Magyarország – Angol
- México & Latinoamérica – Español
- Nederland – Engels
- New Zeeland – English
- Norge – Engelsk
- Österreich – Deutsch
- Polska – Polski
- Portugal – Inglês
- România – Engleză
- Россия – Русский
- Slovensko – Anglický
- Suomi – Englanti
- Sverige – Engelska
- Schweiz – Deutsch
- Suisse – Français
- Türkiye – Türkçe
- Україна – Англійська
- United Kingdom – English
- U.S.A. – English
You are about to leave www.ucbsuisse.ch.
Dieser Link öffnet in einem neuen Fenster eine Webseite eines anderen Anbieters, für deren Inhalte die UCB Pharma GmbH nicht verantwortlich ist.